Abstract
OBJECTIVE: Cervical cancer is caused by human papillomavirus (HPV) infections; however, there are no molecularly defined subtypes, and few approved targeted therapies. We defined molecular subtypes and tested targeted agents. METHODS: Public datasets were analyzed; cell lines were treated with drugs; and donor T cells and their proliferation were measured. RESULTS: We define three molecular subtypes: I, Wild type for PIK3CA/no YAP1 amplification; II, PIK3CA mutation/no YAP1 amplification; III, PIK3CA WT/YAP1 amplification. Patients with YAP1-amplified cervical cancer have poorer survival. The PI3K-specific inhibitors Alpelisib (BYL-719) and Inavolisib (GDC0077) inhibit the proliferation of multiple PIK3CA-mutated cervical cancer cell lines, but not a PIK3CA wild-type (WT) line. The pan-AKT inhibitor, Capivasertib (AZD5363), suppressed some but not all tested PIK3CA-mutated cell lines and one PIK3CA-wt cell line (SiHa). Alpelisib inhibits the expression of the HPV16 E7 oncoprotein, CD274/PD-L1, YAP1, and EGFR genes, only in PI3K-mutated cell lines. Treatment of an HPV16-positive, HLA-A2, PIK3CA mutant cell line (CaSki) with T cells (NexImmune), specific to HPV16 tumor antigens inhibited in a T cell: target cell ratio-dependent manner. BYL-719, in combination with donor T cells, enhances cytotoxicity against CaSki cells. Furthermore, pretreatment with BYL-719 and removing the drug, followed by treatment with donor T cells, had the maximum effect. CONCLUSIONS: Our study revealed molecular inhibitors targeting mutant PIK3CA cervical cancer. When combined with immune therapies, these agents may improve outcomes of advanced HPV16 cancers. Further research on targeted therapies will improve the prognosis of patients with cervical cancer.